This week the take home message asks us to change from “start low and go slow,” to “be aggressive not repressive.” More and more documentation shows the value of adding newer classes of medications sooner to get our patients to target. Part of this comes from the sheer acknowledgement that …

Combination therapy resulting in superior glycemic control, weight loss versus either agent alone

Ertugliflozin provides clinically significant reductions in blood glucose levels.

A single, once-daily injection to lower both fasting and postprandial blood glucose

Are clinicians intensifying treatment before it is too late?

Initiation of glucagon like peptide-1 agonists may increase risk of gallbladder or bile duct disease and cholecystectomy; no increased risk associated with DPP-4 inhibitor therapy.

In part 2 of this exclusive interview from AACE 2016, Dr. Garvey discusses the available tools -- medication, surgery, lifestyle interventions - to combat obesity, and which strategies are most effective.

In part 1 of this exclusive interview from AACE 2016, Dr. Timothy Garvey discusses the new comprehensive clinical practice guidelines for patients with obesity.

Please select the drug class that best fits the description. This shorter-acting insulin secretagogue may be associated with less hypoglycemia than the other secretagogues. 1. Biguanides 2. Sulfonylureas 3. Meglitinides 4. Thiazolidinediones Did you get it right? Follow the link to check your answer.

Should we be more aggressive for people with prediabetes and use more of the drugs we have available, rather than waiting until they progress to diabetes? Follow the link to share your opinion!